Supriya Lifescience Ltd

Supriya Lifescience has experienced a notable rebound, gaining 5.19% on February 12, 2025, after two days of decline. The stock reached an intraday high of Rs 720 and has outperformed its sector. It remains above several key moving averages, reflecting its strong market position and resilience.

Supriya Lifescience's stock has shown significant volatility, experiencing a decline over two consecutive days and a notable intraday fluctuation. While it remains above longer-term moving averages, its short-term performance is mixed. The stock has gained modestly over the past month, contrasting with broader market trends.

Supriya Lifescience's stock faced a decline of 6.18% on February 10, 2025, underperforming its sector. Despite this drop, the stock has gained 10.40% over the past month. Its moving averages present a mixed picture, highlighting the complexities of market sentiment in the pharmaceutical industry.

Supriya Lifescience experienced a notable rebound in its stock performance on February 4, 2025, gaining 6.1% after two days of decline. The stock outperformed its sector and is currently trading above multiple moving averages, indicating a positive trend despite a slight decline over the past month.

Supriya Lifescience experienced a notable rebound in its stock performance on February 4, 2025, gaining 6.1% after two days of decline. The stock outperformed its sector and is currently trading above multiple moving averages, indicating a positive trend despite a slight decline over the past month.

Supriya Lifescience has demonstrated notable performance in the Pharmaceuticals & Drugs sector, gaining 5.28% on January 30, 2025. The stock has outperformed the Sensex and is trading above several key moving averages, reflecting strong market momentum and a positive trend over the past few days.

Supriya Lifescience, a midcap pharmaceutical company, experienced a notable rebound on January 29, 2025, gaining 5.48% after three days of decline. The stock outperformed its sector and reached an intraday high of Rs 658, indicating a potential recovery amid recent volatility in the market.

Supriya Lifescience, a midcap pharmaceutical company, experienced a notable rebound on January 29, 2025, gaining 5.48% after three days of decline. The stock outperformed its sector and reached an intraday high of Rs 658, indicating a potential recovery amid recent volatility in the market.

Supriya Lifescience, a midcap pharmaceutical company, experienced a notable rebound on January 29, 2025, gaining 5.48% after three days of decline. The stock outperformed its sector and reached an intraday high of Rs 658, indicating a potential recovery amid recent volatility in the market.

Supriya Lifescience has faced significant stock volatility, declining notably today and over the past three days. Despite a brief intraday gain, the stock remains below several key moving averages. Its recent performance contrasts with the broader market, indicating challenges in the current market environment.

Supriya Lifescience's stock has seen a decline of 5.09% today, continuing a downward trend over two days with a total drop of 9.18%. Despite reaching an intraday high, the stock underperformed compared to its sector and has faced challenges in the current market environment.

Supriya Lifescience has announced its financial results for Q3 FY24-25, highlighting significant growth in net sales, operating profit, and profitability metrics. The company achieved record net sales of Rs 185.65 crore and reported its highest profit levels in five quarters, reflecting a strong market position and operational efficiency.

Supriya Lifescience, a midcap pharmaceutical company, saw a significant decline on January 24, 2025, reversing a brief period of gains. The stock fluctuated between an intraday high and low, underperforming its sector. Despite being above longer-term moving averages, it has experienced a slight decline over the past month.

Supriya Lifescience, a midcap pharmaceutical company, faced a decline of 5.7% on January 22, 2025, contributing to an 8.65% drop over two days. The stock has underperformed its sector and declined 9.04% over the past month, yet remains above its 100-day and 200-day moving averages.

Supriya Lifescience has recently adjusted its evaluation, reflecting a reassessment of its market position. The company has demonstrated strong operational stability, with a notable operating profit growth and solid financial metrics, attracting increased institutional investment and showcasing significant market outperformance over the past year.

Supriya Lifescience has recently undergone a revision in its score, reflecting ongoing challenges in the pharmaceuticals sector. The stock has been added to MarketsMOJO's list, indicating a shift in evaluation amid a notable decline in performance metrics. Despite being above longer-term moving averages, short-term trends remain concerning.

Supriya Lifescience has recently undergone a revision in its score following a notable decline in stock performance. The company, a midcap player in the pharmaceuticals sector, has faced consecutive losses, underperforming against its sector and broader market trends. Additionally, it has been added to MarketsMOJO's list, reflecting ongoing evaluations of its market position and financial metrics.

Supriya Lifescience has seen a revision in its score following a strong performance, gaining 5.21% on December 31, 2024, and outperforming its sector. The stock has been added to MarketsMOJO's list, reflecting its solid market position despite a recent monthly decline. The outlook remains stable amid fluctuating market conditions.